Dear colleagues

Oncoletter is proud having been invited to record Cancer Center Zürich's Second Zurich Immuno-Oncology Symposium.

As Prof. Dr. Rolf Stahel, Chair and Prof. Dr. Michael Weller, Deputy Chair, are writing in their welcome address immunotherapy with immune checkpoint inhibitors has become a reality for patients with metastatic melanoma, advanced non-small cell lung cancer, bladder cancer, renal cell cancer and Hodgkin Disease. Available data indicate patients with many other malignant diseases are likely to benefit from this form of therapy.

The advent of immunotherapy brings new opportunities, but also new challenges to physicians advising patients and treating patients. We invite you to take part in the Second Zurich Immuno-Oncology Symposium of the Cancer Center Zürich to familiarize yourself with the current and future developments and to meet an experienced international faculty.

This report has been financed by Cancer Center Zürich